Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 20, 2021
Event: Entry into a Material Definitive Agreement (Open Market Sale Agreement).
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data point disclosed is the authorization of a capital raising program:
- Maximum Aggregate Gross Proceeds: Up to $90.0 million.
- Commission to Sales Agent: 3.0% of aggregate gross proceeds.
- Underlying Registration: Form S-3 (File No. 333-238849), effective June 10, 2020.
Material Changes
The filing discloses the execution of an "at-the-market" offering program with Jefferies LLC. This agreement allows the Company to sell shares of its common stock from time to time at its sole discretion. No material changes to prior period financial results are reported in this document.
Guidance, Outlook, and Risks
Management Commentary: The Company may instruct Jefferies not to sell shares if sales cannot be effected at or above a designated price. The agreement may be terminated by either party or upon the sale of all shares subject to the agreement.
Risks and Contingencies: The filing notes that the report does not constitute an offer to sell shares in any jurisdiction where such an offer would be unlawful prior to registration. The Company is identified as an emerging growth company.
Investor Verification Checklist
- Verify the current market price of IDEAYA Biosciences common stock (IDYA) to assess potential dilution impact.
- Review the full text of the Open Market Sale Agreement (Exhibit 1.1) for specific termination rights and price designation mechanisms.
- Confirm the status of the underlying Form S-3 registration statement (File No. 333-238849).
- Monitor future filings for actual sales volumes and proceeds generated under this program.